This is a paid press release. Contact the press release distributor directly with any inquiries.

MacroGenics to Participate in Upcoming Investor Conferences

MacroGenics, Inc.

Fri, February 27, 2026 at 7:30 AM GMT+9 2 min read

In this article:

MGNX

+3.13%

MacroGenics, Inc.

ROCKVILLE, MD, Feb. 26, 2026 (GLOBE NEWSWIRE) – MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company’s management team will participate in the following investor conferences in March:

**TD Cowen 46th Annual Health Care Conference (Boston, MA).** MacroGenics’ President and CEO, Eric Risser, will participate in a hybrid presentation and fireside chat on Tuesday, March 3, at 3:10 pm ET. MacroGenics’ management will also participate in one-on-one meetings.

**Leerink ****Partners 2026 Global Healthcare Conference (Miami, FL).** Mr. Risser will participate in a fireside chat on Tuesday, March 10, at 1:40 pm ET. MacroGenics’ management will also participate in one-on-one meetings.

**The Citizens 2026 Life Sciences Conference (Miami, FL). **Mr. Risser will participate in a fireside chat on Wednesday, March 11, at 10:45 am ET. MacroGenics’ management will also participate in one-on-one meetings.

**Barclays 28th Annual Global Healthcare Conference (Miami, FL). **Mr. Risser will participate in a fireside chat on Thursday, March 12, at 10:00 am ET. MacroGenics’ management will also participate in one-on-one meetings.

Webcasts of these presentations may be accessed under “Events & Presentations” in the Investor Relations section of MacroGenics’ website at The Company will maintain an archived replay of the webcasts on its website for 30 days.

About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics’ technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company’s website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

CONTACT: Contacts: Jim Karrels, Senior Vice President, CFO 1-301-251-5172 info@macrogenics.com Argot Partners 1-212-600-1902 macrogenics@argotpartners.com

Terms and Privacy Policy

Privacy Dashboard

More Info